Orchid Pharma (ORCHPHARMA) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 sales declined 29% year-over-year to INR 173 crore due to a global antibiotics market slowdown, with both prices and volumes under pressure.

• Gross margins were maintained at 42% by avoiding price wars and optimizing product mix and input costs, though some reports show a decline to 39%.

• Operational EBITDA for Q1 FY26 was INR 14 crore, with operating costs remaining flat despite ongoing investments in growth initiatives.

• Strategic acquisition of global rights to Enmetazobactam and Exblifep from Allecra, positioning the company as the sole Indian innovator of an internationally approved new chemical entity.

• Board approved unaudited standalone and consolidated financial results for Q1 FY26, with statutory auditors expressing an unmodified opinion on standalone and a modified opinion on consolidated results.

Financial highlights

• Q1 FY26 sales: INR 173 crore, down from INR 244 crore in Q1 FY25; FY25 sales rose 13% to INR 922 crore.

• Q1 FY26 EBITDA dropped 27% to INR 30 crore; FY25 EBITDA increased 11% to INR 156 crore.

• Q1 FY26 PAT declined 38% to INR 18 crore; FY25 PAT grew 12% to INR 106 crore.

• Standalone net profit for Q1 FY26 was ₹1,819.74 lakhs, consolidated net profit was ₹1,475.58 lakhs.

• Basic and diluted EPS (standalone) for Q1 FY26 were ₹3.59.

Outlook and guidance

• No near-term revival expected in the antibiotics market; management anticipates continued volume and price pressure for the rest of the year.

• Focus remains on global expansion of Exblifep, deepening domestic penetration, and progressing the 7ACA project.

• Targeting U.S. out-licensing of Enmetazobactam within a year of acquisition completion.

• Ongoing amalgamation and capital deployment from QIP proceeds indicate strategic growth focus.